A human monoclonal anti-CCN2 antibody, known as FG-3019 or Pamrevlumab, has been developed and is in phase 3 clinical trials for use in treating multiple diseases, including Duchene muscular dystrophy and idiopathic pulmonary fibrosis [26,27,28,29]. This evidence concerns the gene CCN2 and pulmonary fibrosis.